[ad_1]
“The Danish Board of Health has concluded that the benefits of using Johnson & Johnson’s COVID-19 vaccine do not outweigh the risks of possible side effects … for those who receive the vaccine,” the agency said in a statement.
“Therefore, the Danish Board of Health will continue the Danish mass vaccination program against COVID-19 without the COVID-19 vaccine from Johnson & Johnson,” he added.
Both the World Health Organization (WHO) and the European Medicines Agency (EMA) have approved J&J vaccines.
The drug was reported to have been removed from the program following reports of several unusual platelet clots with a decrease in platelet count among J&J vaccinated people in the United States.
The EVA said on April 20 that unusual blood clots should be described as a “very rare” side effect of the J&J coronavirus vaccine, but stressed that the benefits of these vaccines still outweigh the risks.
J&J had delayed the distribution of its single-dose vaccine in Europe, and decided to wait for EVA to publish the results of its study, but said it had “great confidence” in its vaccine.
In April, Denmark announced that it would no longer use the AstraZeneca vaccine against the pandemic coronavirus, following rare but serious cases of blood clots in people who had been vaccinated.
Despite the WHO and EEA recommendations to continue vaccination with the vaccine, “the Danish vaccination campaign will continue without the AstraZeneca vaccine,” said Soren Brostrom, director of the Danish Board of Health.
Denmark was the first country in Europe to stop using AstraZeneca.
Dozens followed the Danish example, but all but a few resumed vaccination with the vaccine, with the EVA emphasizing the benefits of the vaccine and saying it considered it “safe and effective.”
[ad_2]
